BR112017025263A2 - método para o tratamento de doença neurológica - Google Patents
método para o tratamento de doença neurológicaInfo
- Publication number
- BR112017025263A2 BR112017025263A2 BR112017025263A BR112017025263A BR112017025263A2 BR 112017025263 A2 BR112017025263 A2 BR 112017025263A2 BR 112017025263 A BR112017025263 A BR 112017025263A BR 112017025263 A BR112017025263 A BR 112017025263A BR 112017025263 A2 BR112017025263 A2 BR 112017025263A2
- Authority
- BR
- Brazil
- Prior art keywords
- treating neurological
- neurological disease
- neurological disorders
- treating
- prophylaxis
- Prior art date
Links
- 208000012902 Nervous system disease Diseases 0.000 title abstract 3
- 208000025966 Neurological disease Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 230000000694 effects Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Epoxy Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
a presente invenção se refere a um inibidor da atividade de csf-1r para o uso no tratamento e/ou profilaxia de doenças neurológicas e novo método de tratamento de doenças neurológicas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15169367 | 2015-05-27 | ||
PCT/EP2016/061824 WO2016189045A1 (en) | 2015-05-27 | 2016-05-25 | Method for the treatment of neurological disease |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017025263A2 true BR112017025263A2 (pt) | 2018-08-07 |
Family
ID=53284033
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017025263A BR112017025263A2 (pt) | 2015-05-27 | 2016-05-25 | método para o tratamento de doença neurológica |
Country Status (16)
Country | Link |
---|---|
US (1) | US10316097B2 (pt) |
EP (1) | EP3303390A1 (pt) |
JP (2) | JP6851322B2 (pt) |
KR (1) | KR20180012279A (pt) |
CN (2) | CN113940996A (pt) |
AR (1) | AR104755A1 (pt) |
AU (1) | AU2016269065B2 (pt) |
BR (1) | BR112017025263A2 (pt) |
CA (1) | CA2987146A1 (pt) |
CO (1) | CO2017011778A2 (pt) |
EA (1) | EA039951B1 (pt) |
IL (1) | IL255506A (pt) |
MA (1) | MA47395A (pt) |
MX (1) | MX2017014782A (pt) |
MY (1) | MY195000A (pt) |
WO (1) | WO2016189045A1 (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020515555A (ja) * | 2017-03-28 | 2020-05-28 | ノバルティス アーゲー | 多発性硬化症の新規治療方法 |
WO2018222957A1 (en) * | 2017-06-01 | 2018-12-06 | Ovid Therapeutics Inc. | Treatment of developmental disorders with imidazolone derivatives |
CN113301960A (zh) * | 2018-12-13 | 2021-08-24 | 财团法人生物技术开发中心 | 抗人类csf-1r抗体和其用途 |
CN113473849A (zh) * | 2019-01-28 | 2021-10-01 | 公益财团法人实验动物中央研究所 | 具有人il-34的非人动物及其用途 |
CN114835811B (zh) * | 2019-12-24 | 2024-03-26 | 宝船生物医药科技(上海)有限公司 | 抗csf1r分子及其用途 |
CN112924698A (zh) * | 2021-03-05 | 2021-06-08 | 厦门大学 | 一种用于诊断神经退行性疾病的生物标志物及其应用 |
Family Cites Families (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
DK336987D0 (da) | 1987-07-01 | 1987-07-01 | Novo Industri As | Immobiliseringsmetode |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
DE768377T1 (de) | 1988-09-02 | 1998-01-02 | Dyax Corp | Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
WO1992002551A1 (en) | 1990-08-02 | 1992-02-20 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
ES2315612T3 (es) | 1991-04-10 | 2009-04-01 | The Scripps Research Institute | Genotecas de receptores heterodimericos usando fagemidos. |
GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US5807683A (en) | 1992-11-19 | 1998-09-15 | Combichem, Inc. | Combinatorial libraries and methods for their use |
WO1995015982A2 (en) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Process for generating specific antibodies |
ES2201097T3 (es) | 1994-01-31 | 2004-03-16 | Trustees Of Boston University | Bibliotecas de anticuerpos policlonales. |
FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
US5738996A (en) | 1994-06-15 | 1998-04-14 | Pence, Inc. | Combinational library composition and method |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
GB9720054D0 (en) | 1997-09-19 | 1997-11-19 | Celltech Therapeutics Ltd | Biological products |
GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
WO2001030381A2 (de) * | 1999-10-28 | 2001-05-03 | Hofbauer, Reinhold | Verwendung von csf-1-inhibitoren |
US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
AU2003295437A1 (en) * | 2002-11-12 | 2004-06-03 | Incyte Corporation | Receptors and membrane-associated proteins |
AU2003285578B2 (en) | 2002-12-03 | 2010-07-15 | Ucb Pharma S.A. | Assay for identifying antibody producing cells |
GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
AU2004253738A1 (en) | 2003-07-01 | 2005-01-13 | Ucb Pharma S.A. | Modified antibody Fab fragments |
GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
GB0619291D0 (en) | 2006-09-29 | 2006-11-08 | Ucb Sa | Altered antibodies |
WO2009026303A1 (en) | 2007-08-21 | 2009-02-26 | Amgen Inc. | Human c-fms antigen binding proteins |
WO2009040562A1 (en) | 2007-09-26 | 2009-04-02 | Ucb Pharma S.A. | Dual specificity antibody fusions |
KR20090090487A (ko) * | 2008-02-21 | 2009-08-26 | 재단법인서울대학교산학협력재단 | 글루코코르티코이드계 화합물을 포함하는 뇌신경질환의 치료 또는 예방용 약학 조성물 |
HUE028756T2 (en) * | 2008-03-14 | 2017-01-30 | Transgene Sa | Anti-CSF-1R antibody |
US8470977B2 (en) * | 2008-03-14 | 2013-06-25 | Transgene S.A. | Antibody against the CSF-1R |
LT2334705T (lt) | 2008-09-26 | 2017-03-27 | Ucb Biopharma Sprl | Biologiniai produktai |
WO2010062399A2 (en) * | 2008-11-26 | 2010-06-03 | Five Prime Therapeutics, Inc. | Csf1r extracellular domain fusion molecules and treatments using same |
EP2424552B1 (en) * | 2009-04-29 | 2017-03-01 | PuraPharm International (H.K.) Limited | Ganoderma lucidum extracts for treating parkinson's disease |
WO2011030107A1 (en) | 2009-09-10 | 2011-03-17 | Ucb Pharma S.A. | Multivalent antibodies |
GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
US9169323B2 (en) | 2010-03-05 | 2015-10-27 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
CA2789071C (en) | 2010-03-05 | 2018-03-27 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
AR080698A1 (es) | 2010-04-01 | 2012-05-02 | Imclone Llc | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e |
EP2566517B1 (en) * | 2010-05-04 | 2018-10-24 | Five Prime Therapeutics, Inc. | Antibodies that bind csf1r |
US9161968B2 (en) * | 2011-04-08 | 2015-10-20 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists |
EA023999B1 (ru) * | 2011-05-05 | 2016-08-31 | Новартис Аг | Ингибиторы csf-1r для лечения опухолей головного мозга |
EP2812355A4 (en) * | 2012-02-06 | 2016-03-02 | Hoffmann La Roche | COMPOSITIONS AND METHODS OF USE OF CSF1R INHIBITORS |
US9358235B2 (en) * | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
US20150119267A1 (en) * | 2012-04-16 | 2015-04-30 | Sloan-Kettering Institute For Cancer Research | Inhibition of colony stimulating factor-1 receptor signaling for the treatment of brain cancer |
CN103127164A (zh) * | 2013-01-06 | 2013-06-05 | 威海康博尔生物药业有限公司 | 一种调节小胶质细胞激活状态的κ-卡拉胶寡糖的应用 |
GB201315487D0 (en) * | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
JOP20200096A1 (ar) * | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
SG11201702723VA (en) * | 2014-10-29 | 2017-05-30 | Five Prime Therapeutics Inc | Combination therapy for cancer |
US10703813B2 (en) * | 2014-12-19 | 2020-07-07 | Universite De Nantes | Anti IL-34 antibodies |
CN107810012A (zh) * | 2015-06-02 | 2018-03-16 | 豪夫迈·罗氏有限公司 | 使用抗il‑34抗体治疗神经疾病的组合物和方法 |
-
2016
- 2016-05-25 EA EA201792610A patent/EA039951B1/ru unknown
- 2016-05-25 EP EP16727353.1A patent/EP3303390A1/en not_active Withdrawn
- 2016-05-25 WO PCT/EP2016/061824 patent/WO2016189045A1/en active Application Filing
- 2016-05-25 KR KR1020177036084A patent/KR20180012279A/ko unknown
- 2016-05-25 MA MA047395A patent/MA47395A/fr unknown
- 2016-05-25 US US15/577,035 patent/US10316097B2/en not_active Expired - Fee Related
- 2016-05-25 BR BR112017025263A patent/BR112017025263A2/pt active Search and Examination
- 2016-05-25 CA CA2987146A patent/CA2987146A1/en not_active Abandoned
- 2016-05-25 CN CN202111207345.0A patent/CN113940996A/zh active Pending
- 2016-05-25 AU AU2016269065A patent/AU2016269065B2/en not_active Expired - Fee Related
- 2016-05-25 MX MX2017014782A patent/MX2017014782A/es unknown
- 2016-05-25 MY MYPI2017704420A patent/MY195000A/en unknown
- 2016-05-25 CN CN201680030517.2A patent/CN107660152B/zh not_active Expired - Fee Related
- 2016-05-25 JP JP2017561376A patent/JP6851322B2/ja active Active
- 2016-05-27 AR ARP160101526A patent/AR104755A1/es unknown
-
2017
- 2017-11-07 IL IL255506A patent/IL255506A/en unknown
- 2017-11-20 CO CONC2017/0011778A patent/CO2017011778A2/es unknown
-
2020
- 2020-11-24 JP JP2020194268A patent/JP2021059541A/ja not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
AR104755A1 (es) | 2017-08-09 |
JP2018522826A (ja) | 2018-08-16 |
EP3303390A1 (en) | 2018-04-11 |
US10316097B2 (en) | 2019-06-11 |
AU2016269065A1 (en) | 2017-12-07 |
EA201792610A1 (ru) | 2018-06-29 |
MY195000A (en) | 2022-12-30 |
AU2016269065B2 (en) | 2022-06-02 |
CA2987146A1 (en) | 2016-12-01 |
US20180142026A1 (en) | 2018-05-24 |
KR20180012279A (ko) | 2018-02-05 |
CN113940996A (zh) | 2022-01-18 |
JP6851322B2 (ja) | 2021-03-31 |
MX2017014782A (es) | 2018-02-15 |
CN107660152A (zh) | 2018-02-02 |
IL255506A (en) | 2018-04-30 |
EA039951B1 (ru) | 2022-03-31 |
CN107660152B (zh) | 2021-11-05 |
WO2016189045A1 (en) | 2016-12-01 |
MA47395A (fr) | 2019-12-11 |
CO2017011778A2 (es) | 2018-04-19 |
JP2021059541A (ja) | 2021-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017025263A2 (pt) | método para o tratamento de doença neurológica | |
BR112018010464A2 (pt) | formulações farmacêuticas tópicas para tratar condições inflamatórias relacionadas | |
BR112018000691A2 (pt) | inibidores peptídicos do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias | |
DOP2016000195A (es) | Compuestos | |
BR112017021021A2 (pt) | inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer | |
EA201891910A1 (ru) | Гетероарильные ингибиторы pad4 | |
EA201691872A1 (ru) | Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств | |
GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
UY39413A (es) | Compuestos inhibidores de metaloenzimas | |
EA201890185A1 (ru) | Способы лечения опосредованных гепсидином нарушений | |
BR112018011709A2 (pt) | inibidores bicíclicos de pad4 | |
CR20160352A (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
ECSP17035415A (es) | 2-Amino-5,5-difluoro-6-(fluorometil)-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de BACE1 | |
GT201700099A (es) | 2- amino-6-(difluorometil)-5,5-difluoro-6-fenil-3, 4, 5, 6-tetrahidropiridinas como inhibidores de bace1 | |
BR112019001039A2 (pt) | composição para uso no tratamento de transtorno depressivo maior | |
EA201792604A1 (ru) | Ингибиторы аутотаксина и их применения | |
BR112018011633A2 (pt) | inibidores de aza-benzimidazol de pad4 | |
UY36868A (es) | Composiciones para tratamiento de enfermedades mediadas por interleuquina 5 (il-5) | |
MX2019001376A (es) | Composicion de liberacion modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabolicos relacionados. | |
BR112018000776A2 (pt) | métodos para tratamento de câncer usando apilimod | |
BR112017009000A2 (pt) | apilimod para uso no tratamento de melanoma | |
BR112018069682A2 (pt) | métodos de tratamento para doenças colestáticas e fibróticas | |
BR112018008931A2 (pt) | ?compostos para tratamento de distúrbios hipoproliferativos? | |
CL2016002321A1 (es) | Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios. | |
BR112016015578A2 (pt) | Inibidores de 17beta-hidroxiesteroide desidrogenases tipo 1 e tipo 2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |